文献速递呼吸危重症与机械通气

同种异体间充质干细胞治疗中重度ARDS的2a期安全性试验

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
PubMed 文献 · Lancet Respir Med · 2018-11-16

START研究是一项前瞻性、双盲、多中心、随机2a期试验,在美国5个中心纳入60例接受机械通气的中重度ARDS患者,按2:1随机接受单次静脉10×10^6/kg间充质干细胞或安慰剂。结论认为单次静脉MSC在mARDS中安全,但需更大试验评估疗效并提高细胞活率。

要点

  • 单次静脉MSC未触发预设的血流动力学或呼吸不良事件。
  • MSC活率范围为36%至85%,需改进细胞活率。

核心结论

  • 单次静脉注射MSC在中重度ARDS患者中安全。
  • 需更大规模试验评估疗效,且必须提高MSC活率。

研究设计与样本

  • 前瞻性、双盲、多中心、随机2a期试验,在美国5个大学医学中心开展。
  • 纳入接受机械通气的中重度ARDS患者(PaO2/FiO2<27 kPa且PEEP≥8 cm H2O)。
  • 按2:1随机接受10×10^6/kg预测体重MSC或安慰剂,共60例合格患者接受治疗。
  • 主要终点为安全性,所有分析按意向性治疗进行。

主要发现

  • 无患者发生任何预设的MSC相关血流动力学或呼吸不良事件。
  • MSC组1例患者在输注后24小时内死亡,判定可能与MSC无关。
  • 基线时MSC组APACHE III评分、分钟通气量和PEEP均值数值上高于安慰剂组。

关键数值与推荐

  • 中重度ARDS定义:PaO2/FiO2<27 kPa且PEEP≥8 cm H2O。
  • MSC剂量:10×10^6/kg预测体重,单次静脉给药。
  • MSC活率范围为36%至85%。

临床怎么用

  • 为中重度ARDS患者静脉输注MSC未出现预设安全性事件,但需监测输注后反应。
  • MSC活率变异大,临床使用前需关注细胞产品质量。
  • 当前证据不支持常规使用MSC治疗ARDS,疗效需更大试验确认。

局限性

  • 2a期试验样本量小(60例),主要终点为安全性而非疗效。
  • 基线时MSC组病情严重程度数值上高于安慰剂组。
  • MSC活率范围宽(36%-85%),可能影响治疗一致性。
  • 随访限于28天死亡率等短期指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has shown benefits in preclinical models of acute respiratory distress syndrome (ARDS). Safety has not been established for administration of MSCs in critically ill patients with ARDS. We did a phase 2a trial to assess safety after administration of MSCs to patients with moderate to severe ARDS. METHODS: We did a prospective, double-blind, multicentre, randomised trial to assess treatment with one intravenous dose of MSCs compared with placebo. We recruited ventilated patients with moderate to severe ARDS (ratio of partial pressure of oxygen to fractional inspired oxygen <27 kPa and positive end-expiratory pressure [PEEP] ≥8 cm H2O) in five university medical centres in the USA. Patients were randomly assigned 2:1 to receive either 10 × 106/kg predicted bodyweight MSCs or placebo, according to a computer-generated schedule with a variable block design and stratified by site. We excluded patients younger than 18 years, those with trauma or moderate to severe liver disease, and those who had received cancer treatment in the previous 2 years. The primary endpoint was safety and all analyses were done by intention to treat. We also measured biomarkers in plasma. MSC viability was tested in a post-hoc analysis. This trial is registered with ClinicalTrials.gov, number NCT02097641. FINDINGS: From March 24, 2014, to Feb 9, 2017 we screened 1038 patients, of whom 60 were eligible for and received treatment. No patient experienced any of the predefined MSC-related haemodynamic or respiratory adverse events. One patient in the MSC group died within 24 h of MSC infusion, but death was judged to be probably unrelated. 28-day mortality did not differ between the groups (30% in the MSC group vs 15% in the placebo group, odds ratio 2·4, 95% CI 0·5-15·1). At baseline, the MSC group had numerically higher mean scores than the placebo group for Acute Physiology and Chronic Health Evaluation III (APACHE III; 104 [SD 31] vs 89 [33]), minute ventilation (11·1 [3·2] vs 9·6 [2·4] L/min), and PEEP (12·4 [3·7] vs 10·8 [2·6] cm H2O). After adjustment for APACHE III score, the hazard ratio for mortality at 28 days was 1·43 (95% CI 0·40-5·12, p=0·58). Viability of MSCs ranged from 36% to 85%. INTERPRETATION: One dose of intravenous MSCs was safe in patients with moderate to severe ARDS. Larger trials are needed to assess efficacy, and the viability of MSCs must be improved. FUNDING: National Heart, Lung, and Blood Institute.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2018. PMID: 30455077. doi:10.1016/S2213-2600(18)30418-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。